Clinical Study

Life360 Innovations completes clinical study for Contino® incontinence product

bg-4

Life360 Innovations Inc. (Life360 Innovations) has completed its five-year, multi-site Canadian clinical study of the Contino® medical devices. The study demonstrated product safety and significant results for effectiveness along multiple metrics.

Contino® is a self-administered licensed medical device that controls bladder leakage in men. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists, so men can get on with life.

Study participants experienced a mean reduction in absorbent pad weight of 75% while using Contino®, as well as an improvement in scores measuring the frequency, severity and impact of urinary incontinence (UI) on quality of life. Some participants also observed health improvements that related to both urinary function and general health, including improved urge reflex, improved bladder sensitivity, and improved continence. Adverse events related to Contino® were few, minor, and manageable.

“We are excited by the study results and the impact that Contino® can have on the quality of life of men with UI,” says Robert Orr, President & CEO of Life360. “Completing the study is a major product development milestone that will support our regulatory applications to Health Canada and other competent authorities for the Contino® medical devices.”

According to the Canadian Continence Foundation UI affects the lives of more than 1.2 million Canadian men, often as a result of prostate cancer treatments and other medical conditions. Issues with the comfort and safety of existing products, such as diapers, penile clamps, and condom catheters, have left a treatment gap for affected males.

Contino® has been in development for over ten years, culminating with the study led by Dr. Richard Casey, Chief Medical Officer of CMX Research Inc., and Dr. Dean Elterman, staff urologist at Toronto Western Hospital/University Health Network. Dr. Michael Holloway, Vice President Medical of Life360 Innovations, was chair of the medical advisory committee for the study.

For more information on Contino®, please visit mycontino.com or contact:

Robert Orr, President & CEO
Telephone: +1-604-653-0360
Toll Free North America: +1-833-543-3311

About Life360 Innovations Inc.

Life360 Innovations imagines, manufactures and distributes Health Canada Licensed medical devices under the Contino® brand. For more information on Life360 Innovations, visit life360innovations.com.

Cautionary Disclaimer Regarding Forward-Looking Statements and Information

This news release contains certain forward-looking statements concerning Life360 Innovations Holdings Inc. and its’ wholly owned subsidiaries (collectively, the “Companies”) in future periods. Statements that are not historical fact are “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995 and “forward looking information” as that term is defined in National Instrument 51-102 (“NI 51-102”) of the Canadian Securities Administrators (collectively, “forward-looking statements”). This document contains certain forward-looking statements relating, but not limited to, the Company’s expectations, intentions, plans and beliefs. Forward-looking information can often be identified by forward-looking words such as “anticipate”, “believe”, “expect”, “goal”, “plan”, “intend”, “estimate”, “may”, and “will”, or similar words suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions, or statements about future events or performance. Forward-looking information may include estimates of future operations, sales, unit costs, costs of capital projects and the timing of commencement of operations that are based on current expectations that involve a number of business risks and uncertainties.

Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to establish estimated revenues, capital and operating costs varying significantly from estimates, delays in obtaining or failures to obtain required regulatory approvals, inflation, changes in exchange rates, delays in the development of projects and other factors. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from expected results.

Shareholders and prospective investors should be aware that these forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. Shareholders are cautioned not to place undue reliance on forward-looking information. By its nature, forward-looking information involves numerous assumptions, inherent risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and various assumed future events will not occur. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking information whether as a result of new information, future events, or other such factors that affect this information, except as required by law.